Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1310

Sort by

Sort Order Select

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Aleksandr Kulagin, Vadim Ptushkin, MD PhD Professor, Elena Lukina, MD PhD Professor, Elena Gapchenko, MD, Oksana Markova, MD MSc, Eugene Zuev, MD, Dmitry Kudlay, MD PhD Professor

Blood (2019) 134 (Supplement_1): 3748.

https://doi.org/10.1182/blood-2019-125693

Published: 2019

Journal Articles

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Ellen K. Ritchie, MD, Sumaiya K. Miah, BA, Sangmin Lee, MD, Tania Curcio, Pinkal Desai, MDMPH, Jeffrey Ball, MD, Michael B. Samuel, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 3858.

https://doi.org/10.1182/blood-2019-130263

Published: 2019

Journal Articles

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Xiaohong Liu, Wenbing Duan, Jing Wang, MD, Jinsong Jia, Lizhong Gong, Shen-ye Lu, MD, Xiaosu Zhao, PhD, Ying-Jun Chang, Yue-Yun Lai, Hongxia Shi, Yu Wang, Chenhua Yan, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 3823.

https://doi.org/10.1182/blood-2019-128505

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4006.

https://doi.org/10.1182/blood-2019-121936

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Stuart L. Goldberg, MD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Scott Justin Keating, MSc, BSc, Hitesh Bhandari, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 4151.

https://doi.org/10.1182/blood-2019-128290

Published: 2019

Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 87.

https://doi.org/10.1182/blood-2019-122336

Published: 2019

Journal Articles

Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson

Francesco Tambaro, MD PhD, Dristhi Ragoonanan, Sajad Khazal, MD, Demetrios Petropoulos, MD, Priti Tewari, MD, Partow Kebriaei, MD, William G. Wierda, MD PhD, Mira A. Kohorst, MD, Kris Michael Mahadeo, MD

Blood (2019) 134 (Supplement_1): 4495.

https://doi.org/10.1182/blood-2019-132085

Published: 2019

Journal Articles

Germline Variation Predicts Treatment Response in Multiple Myeloma

Kyle Roter, BSc, Donglei Hu, PhD, Alyssa Clay-Gilmour, PhD, Scott Huntsman, Nina D. Shah, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD, Moritz Binder, MDMPH, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Susan L. Slager, PhD, Celine M. Vachon, PhD, Elad Ziv, MD

Blood (2019) 134 (Supplement_1): 4397.

https://doi.org/10.1182/blood-2019-129344

Published: 2019

Journal Articles

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Hsu-Chih Chien, PhD MSc, Vikas Patil, MS, Kelli M Rasmussen, MS, Christina Yong, MA, Juliana M L Biondo, MD, Mary Halloran, PharmD, BCPS, Sheila Shapouri, PharmD, MS, Mei Wu, PharmD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD

Blood (2019) 134 (Supplement_1): 4309.

https://doi.org/10.1182/blood-2019-128645

Published: 2019

Journal Articles

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Pauline De Malglaive, MD, Matthieu Groh, MD, Guillaume Lefèvre, MD PhD, Chafika Morati Hafsaoui, MD, Magda Alexis, MD, Mathilde Hunault, MD PhD, Julien Seneschal, MD PhD, Hilaire Charlanne, MD, Claude Preudhomme, PharmD, PhD, Bernard Bonnotte, MD PhD, Jean Emmanuel Kahn, PhDMD

Blood (2019) 134 (Supplement_1): 2322.

https://doi.org/10.1182/blood-2019-131687

Published: 2019

Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD

Blood (2019) 134 (Supplement_1): 2752.

https://doi.org/10.1182/blood-2019-129823

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Journal Articles

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, Mignon L. Loh, MD, Peter C. Adamson

Blood (2019) 134 (Supplement_1): 2586.

https://doi.org/10.1182/blood-2019-123710

Published: 2019

NARROW

AL patients don’t dare go without dara

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson

Germline Variation Predicts Treatment Response in Multiple Myeloma

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only